Date: 2011-04-08
Type of information: Production agreement
Compound: CTXcryo® stem cell product
Company: ReNeuron (UK) NHS Blood and Transplant (UK)
Therapeutic area: Cardiovascular diseases
Type agreement: manufacturing
production
Action mechanism:
Disease: peripheral arterial disease
Details: ReNeuron Group is expanding its contract manufacturing arrangements in the UK by signing an agreement with NHS Blood and Transplant (NHSBT) to develop and manufacture its CTXcryo® stem cell product to clinical and commercial grade standards.
Following completion of ongoing technology transfer work, NHS Blood and Transplant (NHSBT) will use their state-of-the-art, accredited cell manufacturing facilities to develop and manufacture ReNeuron’s next-generation CTXcryo® frozen stem cell product for pre-clinical development work and eventual clinical use in the Company’s ReN009 programme for peripheral arterial disease and in other future therapeutic programmes.
The manufacturing arrangements with NHSBT complement ReNeuron’s ongoing contract manufacturing arrangements with Angel Biotechnology plc in Scotland, where product development and testing also takes place with ReNeuron’s cell products and where its CTX cells are manufactured for clinical use in the Company’s ReN001 stroke programme. The Company intends to further broaden its contract manufacturing arrangements into other territories, including the US, in due course in order to meet the needs of its ongoing clinical and product development strategy.
Financial terms:
Latest news:
